All In Biotech

Drug Trial Radar · NCT01275066

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Last checked: Nov 20, 2026Latest source record: Jul 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

177

Actual

Start

Feb 2011

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jan 12, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will evaluate the efficacy and safety of 2.0 mg/kg/week BMN 110 and 2.0 mg/kg/every other week BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A Syndrome). There is currently no standard accepted treatment for MPS IVA other than supportive care. Enzyme replacement therapy (ERT) may be a potential new treatment option for MPS IVA patients. BMN 110 is administered to MPS IVA patients by IV infusion, allowing cellular uptake by the mannose-6-phosphate receptor and transportation to the lysosomes. This enzyme uptake into the lysosomes is hypothesized to promote increased catabolism of keratan sulfate (KS) in tissue macrophages, hyaline cartilage, other connective tissues, and heart valve, and reduce the progressive accumulation of KS which is responsible for the clinical manifestations of the disorders.

Conditions

  • MPS IV A

Interventions

  • BMN 110 WeeklyDrug

    BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.

  • PlaceboDrug

    Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.

  • BMN 110 Every Other WeekDrug

    BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Endurance as Measured by the 6-minute Walk TestTime frame: Baseline to Week 24

Locations

28 sites in 17 countries. Site status is shown where the registry gives one.

  • Site not named

    Oakland, California

  • Site not named

    Wilmington, Delaware

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Chicago, Illinois

  • Site not named

    New York, New York

  • Site not named

    Seattle, Washington

  • Site not named

    Córdoba, Argentina

  • Site not named

    Campina Grande, Brazil

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    Montreal, Canada

  • Site not named

    Sherbrooke, Canada

  • Site not named

    Toronto, Canada

  • Site not named

    Bogotá, Colombia

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Lyon, France

  • Site not named

    Paris, France

  • Site not named

    Mainz, Germany

  • Site not named

    Monza, Italy

  • Site not named

    Tokyo, Japan

  • Site not named

    Amsterdam, Netherlands

  • Site not named

    Coimbra, Portugal

  • Site not named

    Doha, Qatar

  • Site not named

    Riyadh, Saudi Arabia

  • Site not named

    Seoul, South Korea

  • Site not named

    Taipei, Taiwan

  • Site not named

    Birmingham, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.